Proteomic characterization of primary diffuse large B-cell lymphomas in the central nervous system: Laboratory investigation

Journal of Neurosurgery

Volumn 109, Issue 3, 2008, Pages 536-546

  Li, Jie ^a   Okamoto, Hiroaki ^a   Yin, Chunyue ^a   Jagannathan, Jay ^a,e   Takizawa, Jun ^b   Aoki, Sadao ^b   Gläsker, Sven ^a   Rushing, Elisabeth J ^c   Vortmeyer, Alexander O ^a   Oldfield, Edward H ^a   Yamanaka, Ryuya ^d   Zhuang, Zhengping ^a,f  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d NIIGATA UNIVERSITY   (Japan)

^e UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^f NONE   (United States)

Author keywords

B cell lymphoma; Gel electrophoresis; Proteomics; Sporadic systemic lymphoma; Western blot

Indexed keywords

PROTEOME; PROTEIN;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; BRAIN LYMPHOMA; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SEQUENCE ANALYSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING; CASE CONTROL STUDY; CENTRAL NERVOUS SYSTEM TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM NEOPLASMS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROTEINS; PROTEOMICS;

EID: 53449088690     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/JNS/2008/109/9/0536     Document Type: Article

References (66)

1. Adamek D, Moskala M, Kaluza J, Goscinski I: Primary malignant lymphoma of brain. A review of four cases diagnosed by means of CT-guided stereotactic biopsy. Folia Neuropathol 37:27-33, 1999
2. Aho R, Ekfors T, Haltia M, Kalimo H: Pathogenesis of primary central nervous system lymphoma: invasion of malignant lymphoid cells into and within the brain parenchyme. Acta Neuropathol 86:71-76, 1993 (Pubitemid 23249076)
3. Aho R, Jalkanen S, Kalimo H: CD44-hyaluronate interaction mediates in vitro lymphocyte binding to the white matter of the central nervous system. J Neuropathol Exp Neurol 53:295-302, 1994 (Pubitemid 24146868)
4. Aho R, Kalimo H, Salmi M, Smith D, Jalkanen S: Binding of malignant lymphoid cells to the white matter of the human central nervous system: role of different CD44 isoforms, beta 1, beta 2 and beta 7 integrins, and L-selectin. J Neuropathol Exp Neurol 56:557-568, 1997 (Pubitemid 27463097)
5. Aster JC: Diseases of white blood cells, lymph nodes, spleen, and thymus, in Kumar V, Abbas AK, Fausto N (eds): Robbins and Cotran: Pathologic Basis of Disease, ed 7. Philadelphia: Elsevier Saunders, 2005, pp 661-710
6. Bourguignon LY, Gilad E, Peyrollier K, Brightman A, Swanson RA: Hyaluronan-CD44 interaction stimulates Rac1 signaling and PKN gamma kinase activation leading to cytoskeleton function and cell migration in astrocytes. J Neurochem 101:1002-1017, 2007 (Pubitemid 46683879)
7. Carsetti R, Rosado MM, Wardmann H: Peripheral development of B cells in mouse and man. Immunol Rev 197:179-191, 2004 (Pubitemid 38142176)
8. Chiang HL, Terlecky SR, Plant CP, Dice JF: A role for a 70-kilodalton heat shock protein in lysosomal degradation of intracellular proteins. Science 246:382-385, 1989
9. Couet J, de Bernard S, Loosfelt H, Saunier B, Milgrom E, Misrahi M: Cell surface protein disulfide-isomerase is involved in the shedding of human thyrotropin receptor ectodomain. Biochemistry 35:14800-14805, 1996 (Pubitemid 26423813)
10. Coupland SE, Loddenkemper C, Smith JR, Braziel RM, Charlotte F, Anagnostopoulos I, et al: Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma. Invest Ophthalmol Vis Sci 46:3957-3964, 2005 (Pubitemid 44264593)
11. Craig EA, Gambill BD, Nelson RJ: Heat shock proteins: molecular chaperones of protein biogenesis. Microbiol Rev 57:402-414, 1993
12. Dogan A, Bagdi E, Munson P, Isaacson PG: CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol 24:846-852, 2000 (Pubitemid 30366272)
13. Endo S, Zhang SJ, Saito T, Kouno M, Kuroiwa T, Washiyama K, et al: Primary malignant lymphoma of the brain: mutation pattern of rearranged immunoglobulin heavy chain gene. Jpn J Cancer Res 93:1308-1316, 2002 (Pubitemid 36104870)
14. Falini B, Fizzotti M, Pucciarini A, Bigerna B, Marafioti T, Gambacorta M, et al: A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 95:2084-2092, 2000 (Pubitemid 30151649)
15. Feener EP, Shen WC, Ryser HJ: Cleavage of disulfide bonds in endocytosed macromolecules. A processing not associated with lysosomes or endosomes. J Biol Chem 265:18780-18785, 1990
16. Flenghi L, Bigerna B, Fizzotti M, Venturi S, Pasqualucci L, Pileri S, et al: Monoclonal antibodies PG-B6a and PG-B6p recognize, respectively, a highly conserved and a formol-resistant epitope on the human BCL-6 protein amino-terminal region. Am J Pathol 148:1543-1555, 1996 (Pubitemid 26135895)
17. Foss HD, Reusch R, Demel G, Lenz G, Anagnostopoulos I, Hummel M, et al: Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 94:3108-3113, 1999 (Pubitemid 29512717)
18. Freedman RB, Hirst TR, Tuite MF: Protein disulphide isomerase: building bridges in protein folding. Trends Biochem Sci 19:331-336, 1994
19. Fujii A, Ohshima K, Hamasaki M, Makimoto Y, Haraoka S, Utsunomiya H, et al: Differential expression of chemokines, chemokine receptors, cytokines and cytokine receptors in diffuse large B cell malignant lymphoma. Int J Oncol 24:529-538, 2004
20. Furuta M, Weil RJ, Vortmeyer AO, Huang S, Lei J, Huang TN, et al: Protein patterns and proteins that identify subtypes of glioblastoma multiforme. Oncogene 23:6806-6814, 2004 (Pubitemid 39280012)
21. Gatenby RA, Gawlinski ET: The glycolytic phenotype in carcinogenesis and tumor invasion: insights through mathematical models. Cancer Res 63:3847-3854, 2003
22. Gavrilovic IT, Abrey LE: Primary central nervous system lymphoma. Curr Oncol Rep 6:388-395, 2004
23. Girgrah N, Letarte M, Becker LE, Cruz TF, Theriault E, Moscarello MA: Localization of the CD44 glycoprotein to fibrous astrocytes in normal white matter and to reactive astrocytes in active lesions in multiple sclerosis. J Neuropathol Exp Neurol 50:779-792, 1991
24. Glasker S, Vortmeyer AO, Lonser RR, Lubensky IA, Okamoto H, Xia JB, et al: Proteomic analysis of hemangioblastoma cyst fluid. Cancer Biol Ther 5:549-553, 2006 (Pubitemid 43765292)
25. Golshani-Hebroni SG, Bessman SP: Hexokinase binding to mitochondria: a basis for proliferative energy metabolism. J Bioenerg Biomembr 29:331-338, 1997
26. Hagel C, Stavrou DK: CD44 expression in primary and recurrent oligodendrogliomas and in adjacent gliotic brain tissue. Neuropathol Appl Neurobiol 25:313-318, 1999 (Pubitemid 29392711)
27. Hamada T, Yonetani N, Ueda C, Maesako Y, Akasaka H, Akasaka T, et al: Expression of the PAX5/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14)(p13;q32) translocation in Bcell non-Hodgkin's lymphoma. Br J Haematol 102:691-700, 1998 (Pubitemid 28387051)
28. Harada K, Nishizaki T, Kubota H, Harada K, Suzuki M, Sasaki K: Distinct primary central nervous system lymphoma defined by comparative genomic hybridization and laser scanning cytometry. Cancer Genet Cytogenet 125:147-150, 2001 (Pubitemid 32448059)
29. Hochberg FH, Miller DC: Primary central nervous system lymphoma. J Neurosurg 68:835-853, 1988
30. Jacob J, Kelsoe G, Rajewsky K, Weiss U: Intraclonal generation of antibody mutants in germinal centres. Nature 354:389-392, 1991 (Pubitemid 21896846)
31. Jahnke K, Hummel M, Korfel A, Burmeister T, Kiewe P, Klasen HA, et al: Detection of subclinical systemic disease in primary CNS lymphoma by polymerase chain reaction of the rearranged immunoglobulin heavy-chain genes. J Clin Oncol 24:4754-4757, 2006 (Pubitemid 46630939)
32. Jundt F, Kley K, Anagnostopoulos I, Schulze Probsting K, Greiner A, Mathas S, et al: Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease. Blood 99:3060-3062, 2002 (Pubitemid 34525400)
33. Klein U, Goossens T, Fischer M, Kanzler H, Braeuninger A, Rajewsky K, et al: Somatic hypermutation in normal and transformed human B cells. Immunol Rev 162:261-280, 1998 (Pubitemid 28182141)
34. Li J, Zhuang Z, Okamoto H, Vortmeyer AO, Park DM, Furuta M, et al: Proteomic profiling distinguishes astrocytomas and identifies differential tumor markers. Neurology 66:733-736, 2006 (Pubitemid 43739831)
35. Liu YJ, Malisan F, de Bouteiller O, Guret C, Lebecque S, Banchereau J, et al: Within germinal centers, isotype switching of immunoglobulin genes occurs after the onset of somatic mutation. Immunity 4:241-250, 1996 (Pubitemid 26131007)
36. Lossos IS: Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol 23:6351-6357, 2005
37. Mandel R, Ryser HJ, Ghani F, Wu M, Peak D: Inhibition of a reductive function of the plasma membrane by bacitracin and antibodies against protein disulfide-isomerase. Proc Natl Acad Sci U S A 90:4112-4116, 1993 (Pubitemid 23134176)
38. Mangiardi JR, Yodice P: Metabolism of the malignant astrocytoma. Neurosurgery 26:1-19, 1990
39. Mazurek S, Boschek CB, Eigenbrodt E: The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J Bioenerg Biomembr 29:315-330, 1997 (Pubitemid 27498411)
40. Mielli SR, Beitler B, Galperin C, Palou VB, Livramento JA, Machado Ldos R, et al: [Non-Hodgkin lymphoma in adults. Protein profile of CSF and serum in 25 patients.] Arq Neuropsiquiatr 56:769-771, 1998 (Portuguese)
41. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H: Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989. Cancer 74:1383-1397, 1994
42. Montesinos-Rongen M, Kuppers R, Schluter D, Spieker T, Van Roost D, Schaller C, et al: Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment. Am J Pathol 155:2077-2086, 1999
43. Nakamura M, Kishi M, Sakaki T, Hashimoto H, Nakase H, Shimada K, et al: Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 63:737-741, 2003 (Pubitemid 36231967)
44. Nakamura M, Sakaki T, Hashimoto H, Nakase H, Ishida E, Shimada K, et al: Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas. Cancer Res 61:6335-6339, 2001 (Pubitemid 32783233)
45. Nakamura M, Shimada K, Ishida E, Konishi N: Histopathology, pathogenesis and molecular genetics in primary central nervous system lymphomas. Histol Histopathol 19:211-219, 2004 (Pubitemid 38111265)
46. Nozaki M, Tada M, Mizugaki Y, Takada K, Nagashima K, Sawamura Y, et al: Expression of oncogenic molecules in primary central nervous system lymphomas in immunocompetent patients. Acta Neuropathol 95:505-510, 1998
47. Okamoto H, Li J, Vortmeyer AO, Jaffe H, Lee YS, Glasker S, et al: Comparative proteomic profiles of meningioma subtypes. Cancer Res 66:10199-10204, 2006 (Pubitemid 44672075)
48. Oudard S, Boitier E, Miccoli L, Rousset S, Dutrillaux B, Poupon MF: Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res 17:1903-1911, 1997 (Pubitemid 27320925)
49. Paulus W, Jellinger K, Morgello S, Deckert-Schlüter M: Malignant lymphomas, in Kleihues P, Cavenee WK (eds): World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC Press, 2000, pp 198-203
50. Ree HJ, Ohsima K, Aozasa K, Takeuchi K, Kim CW, Yang WI, et al: Detection of germinal center B-cell lymphoma in archival specimens: critical evaluation of Bcl-6 protein expression in diffuse large B-cell lymphoma of the tonsil. Hum Pathol 34:610-616, 2003 (Pubitemid 36750374)
51. Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, Lutsch G, Ducasse C, et al: Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem 274:18947-18956, 1999 (Pubitemid 129519312)
52. Roslin M, Henriksson R, Bergstrom P, Ungerstedt U, Bergenheim AT: Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol 61:151-160, 2003 (Pubitemid 36253661)
53. Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, et al: Gene expression and angiotropism in primary CNS lymphoma. Blood 107:3716-3723, 2006
54. Rubenstein JL, Treseler P, O'Brien JM: Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematol Oncol Clin North Am 19:705-717, vii, 2005 (Pubitemid 41096714)
55. Ryser HJ, Levy EM, Mandel R, DiSciullo GJ: Inhibition of human immunodeficiency virus infection by agents that interfere with thiol-disulfide interchange upon virus-receptor interaction. Proc Natl Acad Sci U S A 91:4559-4563, 1994 (Pubitemid 24984912)
56. Sariban-Sohraby S, Magrath IT, Balaban RS: Comparison of energy metabolism in human normal and neoplastic (Burkitt's lymphoma) lymphoid cells. Cancer Res 43:4662-4664, 1983
57. Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P: Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer 89:1375-1382, 2003 (Pubitemid 37363431)
58. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT: Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 101:815-821, 2003 (Pubitemid 36139344)
59. Srivastava B, Lindsley RC, Nikbakht N, Allman D: Models for peripheral B cell development and homeostasis. Semin Immunol 17:175-182, 2005 (Pubitemid 40488976)
60. Stein H, Marafioti T, Foss HD, Laumen H, Hummel M, Anagnostopoulos I, et al: Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 97:496-501, 2001 (Pubitemid 32060336)
61. Sugita Y, Tokunaga O, Nakashima A, Shigemori M: SHP-1 expression in primary central nervous system B-cell lymphomas in immunocompetent patients reflects maturation stage of normal B cell counterparts. Pathol Int 54:659-666, 2004 (Pubitemid 39297290)
62. Tome ME, Briehl MM, Lutz NW: Increasing the antioxidant defense in WEHI7.2 cells results in a more tumor-like metabolic profile. Int J Mol Med 15:497-501, 2005
63. Torlakovic E, Tierens A, Dang HD, Delabie J: The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol 159:1807-1814, 2001 (Pubitemid 33062523)
64. Tuaillon N, Chan CC: Molecular analysis of primary central nervous system and primary intraocular lymphomas. Curr Mol Med 1:259-272, 2001 (Pubitemid 33772047)
65. Turano C, Coppari S, Altieri F, Ferraro A: Proteins of the PDI family: unpredicted non-ER locations and functions. J Cell Physiol 193:154-163, 2002
66. Vogel TW, Zhuang Z, Li J, Okamoto H, Furuta M, Lee YS, et al: Proteins and protein pattern differences between glioma cell lines and glioblastoma multiforme. Clin Cancer Res 11:3624-3632, 2005 (Pubitemid 40685577)